Novo Nordisk AS may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Novo Nordisk's Net Debt is very stable compared to the past year. As of the 20th of March 2025, Retained Earnings is likely to grow to about 151.7 B, while Cash is likely to drop about 8.3 B. Key indicators impacting Novo Nordisk's financial strength include:
The essential information of the day-to-day investment outlook for Novo Nordisk includes many different criteria found on its balance sheet. An individual investor should monitor Novo Nordisk's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Novo Nordisk.
Novo Nordisk competes with Regeneron Pharmaceuticals, Crispr Therapeutics, Sarepta Therapeutics, Intellia Therapeutics, and Moderna. Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Novo Nordisk's current stock value. Our valuation model uses many indicators to compare Novo Nordisk value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novo Nordisk competition to find correlations between indicators driving Novo Nordisk's intrinsic value. More Info.
Novo Nordisk AS is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novo Nordisk AS is roughly 3.60 . At this time, Novo Nordisk's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novo Nordisk's earnings, one of the primary drivers of an investment's value.
Novo Nordisk AS Systematic Risk
Novo Nordisk's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novo Nordisk volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Novo Nordisk AS correlated with the market. If Beta is less than 0 Novo Nordisk generally moves in the opposite direction as compared to the market. If Novo Nordisk Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novo Nordisk AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novo Nordisk is generally in the same direction as the market. If Beta > 1 Novo Nordisk moves generally in the same direction as, but more than the movement of the benchmark.
Novo Nordisk Thematic Clasifications
Novo Nordisk AS is part of several thematic ideas from Giant Impact to Baby Boomer Prospects. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Novo Nordisk Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novo Nordisk's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Novo Nordisk growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Novo Nordisk help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novo Nordisk AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novo Nordisk AS based on widely used predictive technical indicators. In general, we focus on analyzing Novo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novo Nordisk's daily price indicators and compare them against related drivers.
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.292
Dividend Share
11.4
Earnings Share
3.22
Revenue Per Share
65.202
Quarterly Revenue Growth
0.301
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.